ABSTRACT
The purpose was to characterize plasminogen activator inhibitor type 2 (PAI-2) expression in normal human conjunctiva in vivo and in vitro. PAI-2 antigen was assayed by immunostaining and immunoblotting of extracts from normal human conjunctival epithelial lysates and conditioned media (CM) of cultured human conjunctival keratinocytes. Immunostaining of normal human conjunctival epithelia revealed that PAI-2 was found consistently in the superficial keratinocytes and, in some biopsies, also in the lower keratinocyte layers. In all cases, PAI-2 was concentrated around the cell periphery. In extracts of conjunctival epithelia and cultured conjunctival keratinocytes, PAI-2 had an apparent molecular weight of 45 kDa, consistent with the non-glycosylated form. The majority of PAI-2, approximately 90%, was cell associated, however, a small percentage of PAI-2 was released into the CM in a linear manner with time. PAI-2 in the conditioned medium had a higher molecular weight, consistent with a glycosylated form. Conjunctival PAI-2 was active, as shown by its ability to complex with a target enzyme, urokinase plasminogen activator (uPA). Although PAI-2 was detectable both in monolayer (i.e., relatively undifferentiated) conjunctival keratinocyte cultures as well as in stratified (i.e., more differentiated) cultures, steady state levels of PAI-2 were greater in the latter. PAI-2 is constitutively expressed by normal human conjunctival epithelial cells. The expression of PAI-2 throughout all epithelial layers in some biopsies of conjunctiva in vivo contrasts with the previously established distribution of PAI-2 in corneal epithelia, where it is present exclusively in the most superficial (i.e. most highly differentiated) cells. The role of PAI-2 in either tissue is unclear. However, we speculate that its distinct distribution in conjunctival versus corneal epithelia underscores inherent differences between these tissues, and may reflect specific functions of this proteinase inhibitor in both conjunctival and corneal epithelial cells.
Subject(s)
Conjunctiva/enzymology , Plasminogen Activator Inhibitor 2/metabolism , Biopsy , Cell Differentiation , Cell Extracts , Cells, Cultured , Conjunctiva/cytology , Conjunctiva/surgery , Culture Media, Conditioned/analysis , Fluorescein-5-isothiocyanate , Fluorescent Antibody Technique, Indirect , Fluorescent Dyes , Humans , Immunohistochemistry , Keratinocytes/cytology , Keratinocytes/enzymology , Kinetics , Microscopy, Fluorescence , Molecular Weight , Plasminogen Activator Inhibitor 2/chemistry , Tissue Distribution , Urokinase-Type Plasminogen Activator/metabolismABSTRACT
The thickness dependence of the helical antiferromagnetic ordering temperature T(N) was studied for thin Ho metal films by resonant magnetic soft x-ray and neutron diffraction. In contrast with the Curie temperature of ferromagnets, T(N) was found to decrease with film thickness d according to [T(N)(infinity)-T(N)(d)]/T(N)(d) proportional variant (d-d(0))(-lambda(')), where lambda(') is a phenomenological exponent and d(0) is of the order of the bulk magnetic period L(b). These observations are reproduced by mean-field calculations that suggest a linear relationship between d(0) and L(b) in long-period antiferromagnets.
ABSTRACT
The detergent sodium dodecyl sulfate is a well-known inducer of irritant contact dermatitis. In this study we show that sodium dodecyl sulfate induces the serine proteinase inhibitor, plasminogen activator inhibitor type 2, in epidermal keratinocytes. The enhancement in plasminogen activator inhibitor type 2 mRNA and antigen is observed both when sodium dodecyl sulfate is applied topically to normal human skin as well as when it is added to the growth medium of cultured human keratinocytes. In vitro, plasminogen activator inhibitor type 2 mRNA is increased within 4-8 h after addition of the detergent, and the increase in plasminogen activator inhibitor type 2 antigen occurs slightly later. The enhancing effect of sodium dodecyl sulfate on plasminogen activator inhibitor type 2 is not related to nonspecific cell lysis nor is it secondary to induction of tumor necrosis factor alpha. Similarities between our in vitro and in vivo findings lead us to hypothesize that sodium dodecyl sulfate may exert its effect on epidermal plasminogen activator inhibitor type 2 via interaction with the keratinocyte.
Subject(s)
Epidermis/metabolism , Keratinocytes/metabolism , Plasminogen Activator Inhibitor 2/biosynthesis , Sodium Dodecyl Sulfate/pharmacology , Surface-Active Agents/pharmacology , Cells, Cultured , Humans , Immunohistochemistry , In Situ HybridizationABSTRACT
Previous work has shown that activation of the epidermal growth factor receptor by endogenous or exogenous signals markedly enhances survival of cultured keratinocytes upon cellular stress such as passaging. This is due, in part, to epidermal-growth-factor-receptor-dependent expression of Bcl-x(L), an antiapoptotic Bcl-2 homolog. In this study we tested whether epidermal-growth-factor-receptor-dependent signal transduction and attendant Bcl-x(L) expression affected survival of human keratinocytes upon exposure to a frequently encountered apoptotic stimulus, radiation with ultraviolet B. We describe that blocking epidermal-growth-factor-receptor-dependent signal transduction sensitized normal keratinocytes to undergo apoptosis upon ultraviolet B radiation with solar light characteristics. Forced expression of Bcl-x(L) partially but significantly inhibited ultraviolet-B-induced apoptosis of immortalized keratinocytes (HaCaT). Bcl-x(L) overexpression afforded no protection to HaCaT cells against apoptosis induced by binding of an agonist antibody to the death receptor CD95, however. CD95 activation has previously been shown to functionally contribute to apoptosis in ultraviolet-irradiated keratinocytes. These results indicate that epidermal growth factor receptor activation and attendant Bcl-x(L) expression provided a physiologically relevant protective pathway of keratinocytes against ultraviolet-induced but not CD95-dependent apoptosis.
Subject(s)
Apoptosis/radiation effects , ErbB Receptors/physiology , Keratinocytes/radiation effects , Proto-Oncogene Proteins c-bcl-2/physiology , Radiation Protection , Ultraviolet Rays , fas Receptor/physiology , Cells, Cultured , Humans , Keratinocytes/physiology , bcl-X ProteinABSTRACT
Hair follicle formation and maintenance involve intimate interactions between follicular epithelial cells and a group of specialized mesenchymal cells known as the dermal papilla. Using the random primer polymerase chain reaction, we have identified an approximately 1.4 kb osteopontin mRNA that is present in large quantities in cultured rat vibrissa dermal papilla cells but undetectable in cultured rat skin fibroblasts. In situ hybridization showed that the osteopontin gene is expressed in dermal papilla cells of pelage follicles during catagen but not in anagen or telogen. As an acidic glycosylated RGD-containing extracellular matrix protein, osteopontin can function both as a cell attachment protein and as a soluble cytokine playing roles in signaling, cell migration, tissue survival, anti-inflammation, and T-cell-mediated cellular immunity. Our results indicate that the comparison of the mRNA of cultured dermal papilla cells and fibroblasts can lead to the identification of not only anagen-specific genes (e.g., nexin 1), but also a catagen-specific gene. We have thus provided evidence that specific genes are turned on during catagen, which is therefore not simply a passive "degenerative" phase. The functional role of osteopontin in catagen is unclear but it may promote the formation of a tightly aggregated dermal papilla, and/or protect the dermal papilla cells from apoptosis induced by cytokines or hypoxia during catagen.
Subject(s)
Dermis/cytology , Hair Follicle/cytology , Hair Follicle/growth & development , Sialoglycoproteins/genetics , Alopecia/physiopathology , Animals , Base Sequence , Cells, Cultured , Fibroblasts/cytology , Fibroblasts/physiology , Gene Expression/physiology , Mesoderm/cytology , Molecular Sequence Data , Osteopontin , RNA, Messenger/analysis , Rats , Rats, Wistar , Vibrissae/cytologyABSTRACT
This paper gives a general overview of the nature and important mechanisms behind internal loading of phosphorus (P), which is a phenomenon appearing frequently in shallow, eutrophic lakes upon a reduction of the external loading. Lake water quality is therefore not improved as expected. In particular summer concentrations rise and P retention may be negative during most of the summer. The P release originates from a pool accumulated in the sediment when the external loading was high. In most lake sediments, P bound to redox-sensitive iron compounds or P fixed in more or less labile organic forms constitute major fractions--forms that are potentially mobile and eventually may be released to the lake water. The duration of the recovery period following P loading reduction depends on the loading history, but it may last for decades in lakes with a high sediment P accumulation. During the phase of recovery, both the duration and net P release rates from the sediment seem to decline progressively. Internal P loading is highly influenced by the biological structure as illustrated by lakes shifting from the turbid to the clearwater state as a result of, for example, biomanipulation. In these lakes P concentrations may be reduced to 50% of the pre-biomanipulation level and the period with negative retention during summer can thus be reduced considerably. The duration of internal loading can be reduced significantly by different restoration methods such as dredging to remove accumulated P or addition of iron or alum to elevate the sorption capacity of sediments. However, an important prerequisite for achieving long-term benefits to water quality is a sufficient reduction of the external P loading.
Subject(s)
Eutrophication , Fresh Water/chemistry , Phosphorus/analysis , Water Pollutants/analysis , Ecosystem , Geologic Sediments/chemistry , Phosphorus/chemistry , PhytoplanktonABSTRACT
The location of follicular and epidermal stem cells in mammalian skin is a crucial issue in cutaneous biology. We demonstrate that hair follicular stem cells, located in the bulge region, can give rise to several cell types of the hair follicle as well as upper follicular cells. Moreover, we devised a double-label technique to show that upper follicular keratinocytes emigrate into the epidermis in normal newborn mouse skin, and in adult mouse skin in response to a penetrating wound. These findings indicate that the hair follicle represents a major repository of keratinocyte stem cells in mouse skin, and that follicular bulge stem cells are potentially bipotent as they can give rise to not only the hair follicle, but also the epidermis.
Subject(s)
Epidermis/growth & development , Hair Follicle/growth & development , Stem Cells/physiology , Animals , Keratinocytes/cytology , Mice , Mice, Inbred C57BLABSTRACT
Proteinases and their inhibitors are very likely to function as mediators or regulators of the hair growth cycle. Very little information is currently available, however, regarding the specific inhibitors present in human hair follicles at defined stages of their growth cycle. In this study we have analyzed two proteinase inhibitors, plasminogen activator inhibitor type 2 and protease nexin 1, in human hair follicles using in situ hybridization and/or immunohistochemistry. Protease nexin 1 mRNA was found only in the mesenchymal population of the hair follicle, i.e., the follicular papilla cells, during the anagen but not the catagen phase. In contrast, plasminogen activator inhibitor type 2 was localized to several epithelial populations in the follicle: the more differentiated cells of the infundibulum; the companion layer in anagen follicles; and the single layer of outer root sheath cells directly abutting the club hair in telogen follicles. At least some of the plasminogen activator inhibitor type 2 in human follicles appears to be in the relaxed form, as evidenced by strong staining with an antibody that is specific for this form of the inhibitor. This suggests that plasminogen activator inhibitor type 2 interacts with and is cleaved by an endogenous follicular proteinase and supports a constitutive role for this inhibitor in human follicular epithelia.
Subject(s)
Carrier Proteins/analysis , Hair Follicle/chemistry , Plasminogen Activator Inhibitor 2/analysis , Serpins/analysis , Amyloid beta-Protein Precursor , Apoptosis , Carrier Proteins/physiology , Humans , Immunohistochemistry , In Situ Hybridization , Plasminogen Activator Inhibitor 2/genetics , Plasminogen Activator Inhibitor 2/physiology , Protease Nexins , RNA, Messenger/analysis , Receptors, Cell Surface , Serpin E2ABSTRACT
Plasminogen activator inhibitor type 2 (PAI-2) is a serine proteinase inhibitor (serpin), present in high quantities in stratified squamous epithelia. Detergent extracts of human epidermis or cultured keratinocytes contain primarily active, nonglycosylated PAI-2. In keratinocytes, the vast majority of PAI-2 is retained within the cell, supporting the hypothesis that PAI-2 may serve specific intracellular function(s) through interaction with an unknown cytoplasmic proteinase. During interaction with the target proteinase, cleavage of PAI-2 within its reactive site loop leads to the formation of a more stable, "relaxed" conformation (PAI-2r). Using a monoclonal antibody specific for PAI-2r, we demonstrate here that PAI-2r is present in keratinocytes of the granular and basal layers of normal human epidermis. In addition, PAI-2r is detectable in cultured human epidermal keratinocytes, where it is concentrated in a detergent-insoluble fraction within differentiating cells. These data provide evidence for the presence of an endogenous, keratinocyte-derived proteinase that constitutively cleaves intracellular PAI-2 in normal human epidermal keratinocytes. Cleavage of PAI-2 by this proteinase may reflect specific intracellular action of PAI-2 in normal cells. Finally, we demonstrate that a commercially available anti-PAI-2 monoclonal antibody (#3750, American Diagnostica, Greenwich, CT), under native experimental conditions, preferentially recognizes the uncleaved, active form of PAI-2 and does not efficiently detect PAI-2r.
Subject(s)
Epidermis/metabolism , Intracellular Membranes/metabolism , Keratinocytes/metabolism , Plasminogen Activator Inhibitor 2/chemistry , Plasminogen Activator Inhibitor 2/metabolism , Antibodies/immunology , Detergents/pharmacology , Drug Resistance , Endopeptidases/metabolism , Epidermal Cells , Epidermis/drug effects , Humans , Intracellular Membranes/drug effects , Keratinocytes/drug effects , Molecular Conformation , Plasminogen Activator Inhibitor 2/immunology , Plasminogen Activator Inhibitor 2/physiology , Reference ValuesABSTRACT
Antibodies directed against recombinant erythropoietin have been obtained by immunization of rabbits with the hormone in Freund's complete adjuvant. Two sets of antibodies are present in the serum of the immunized rabbits. The results of oxidation of the erythropoietin with periodate, inhibition of the antibodies with the structural monosaccharide residues of the hormone, and reaction of the antibodies with lectins of known carbohydrate specificity have established the antibodies to be anti-carbohydrate antibodies. These antibodies may be of value as tracking agents for some diseases and should be useful for detecting abuses of the hormone in enhancing performance in athletic competitions.
Subject(s)
Antibodies/immunology , Erythropoietin/chemistry , Oligosaccharides/chemistry , Carbohydrate Sequence , Immunodiffusion , Molecular Sequence Data , Oligosaccharides/immunology , Recombinant ProteinsABSTRACT
Cadherin function is required for normal keratinocyte intercellular adhesion and stratification. In the present study, we have investigated whether cadherin-cadherin interactions may also modulate keratinocyte differentiation, as evidenced by alterations in the levels of several differentiation markers. Confluent keratinocyte cultures, propagated in low Ca(2+) medium in which cadherins are not active, were pre-incubated with antibodies that block the function of E-cadherin and/or P-cadherin; Ca(2+ )was then elevated to 1 mM to activate the cadherins and induce differentiation. In control cultures (incubated with no antibody or with antibodies to other cell surface molecules), Ca(2+) elevation induced an increase in type 1 transglutaminase, profilaggrin, and loricrin, as measured by western blotting and in agreement with previous results. However, the concurrent addition of antibodies against both E- and P-cadherin prevented this increase in transglutaminase 1 protein. Incubation with either antibody alone had no consistent effect. Profilaggrin and loricrin, which are later markers of keratinocyte differentiation, responded differently from transglutaminase 1 to addition of antibodies. In the presence of anti-E-cadherin antibody, both loricrin and profilaggrin levels were dramatically enhanced compared to the high Ca(2+) control cells, while addition of antibody to P-cadherin slightly attenuated the Ca(2+)-induced increase. In the presence of both antibodies, loricrin and profilaggrin protein levels were intermediate between those observed in the presence of either antibody alone. The expression of involucrin, however, was unaffected by addition of antibodies. In addition, effects of the anti-cadherin antibodies were not secondary to alterations in proliferation or programmed cell death, as determined by several independent assays of these processes. Thus, the consequences of cadherin inhibition depend upon both the particular cadherin and the differentiation marker under study. Taken together, these data suggest that E-cadherin and P-cadherin contribute to the orderly progression of terminal differentiation in the epidermis in multiple ways.
Subject(s)
Biomarkers , Cadherins/metabolism , Cell Differentiation/physiology , Keratinocytes/cytology , Apoptosis , Cadherins/physiology , Cell Division , Cells, Cultured , Filaggrin Proteins , Humans , Intermediate Filament Proteins/metabolism , Keratinocytes/enzymology , Keratinocytes/ultrastructure , Membrane Proteins/metabolism , Microscopy, Electron , Transglutaminases/metabolismABSTRACT
The role of Src family tyrosine kinases in cellular proliferation is well established; however, their role in cellular differentiation is less well understood. In this study we have investigated the role played by Src in the differentiation of squamous epithelial cells. Transfection of activated Src into A431 cells resulted in morphological changes that resembled epidermal differentiation. When we used Src mutants to characterize the observed phenotypic changes, we found that protein tyrosine kinase activity, correct membrane localization and the activity of the SH2 domain were required, but the SH3 domain was not. Furthermore, downstream activity of Ras was not required for the Src-mediated changes in A431 cells.
Subject(s)
Carcinoma, Squamous Cell/pathology , Epidermis/pathology , Genes, src , Oncogene Protein pp60(v-src)/physiology , Protein-Tyrosine Kinases/physiology , Proto-Oncogene Proteins p21(ras)/physiology , Uterine Cervical Neoplasms/pathology , src Homology Domains , Biomarkers , Cell Adhesion , Cell Differentiation/genetics , Cell Size , Female , Humans , Oncogene Protein pp60(v-src)/chemistry , Phosphorylation , Protein Processing, Post-Translational , Protein-Tyrosine Kinases/chemistry , Protein-Tyrosine Kinases/genetics , Recombinant Fusion Proteins/physiology , Transfection , Tumor Cells, Cultured/ultrastructureABSTRACT
PURPOSE: To examine normal human corneal epithelium in vivo and in vitro for expression and status of plasniinogcn activ:ltor inhibitor type 2 (PAI-2). METHODS: Normal hiuman corneas were prepared for frozen sections and for culture of corneal keratinocytes. PAI-2 was analyzed by immunohistochemistry and western blot analysis uising antibodies that recognize all forms of PAI-2. RESULTS: In vivo and in vitro, PAI-2 was immunohistochemically localized to the superficial corneal keratinocytes. Immunostaining also revealed the presence of PAI-2 in its relaxed (i.e., cleaved) conformation. In vivo, the staining pattern of the relaxed form was identical with that of total PAI-2, but in vitro the relaxed form was detected in a smaller subpopulation of superficial cells. In vitro, the staining pattern indicated a cytoplasmic localization for PAI-2. Western blot analysis revealed that most of the PAI-2 was cell associated and functionally active. CONCLUSIONS: The present results are the first to show that PAI-2 is found in normal human corneal epithelium in vivo and in vitro, where it can be considered as a differentiation product. At least in vitro, all detectable PAI-2 is cell associated, with a cytoplasmic distribution. A subpopulation of keratinocytes also contains PAI-2 in its relaxed (i.e., cleaved) conformation. Cleavage by an as yet unidentified cytoplasmic proteinase may constitute a crucial aspect of the function of corneal epithelial PAI-2, which may be relevant to terminal differentiation and death of the corneal keratinocyte.
Subject(s)
Epithelium, Corneal/chemistry , Plasminogen Activator Inhibitor 2/analysis , Serine Proteinase Inhibitors/analysis , Blotting, Western , Cells, Cultured , Epithelium, Corneal/cytology , Humans , Immunoenzyme TechniquesABSTRACT
The epidermal growth factor receptor has multiple roles in epidermal biology relating to growth, migration, and, as shown recently, survival of keratinocytes. In cultured keratinocytes activation of the epidermal growth factor receptor upregulates expression of Bcl-x(L), an anti-apoptotic Bcl-2 homolog. The functional contribution of epidermal growth factor receptor-dependent Bcl-x(L) expression to keratinocyte survival is poorly understood. Here we demonstrate that inhibition of the epidermal growth factor receptor tyrosine kinase activity with either an epidermal growth factor receptor antagonistic monoclonal antibody (MoAb 425) or an epidermal growth factor receptor-selective tyrosine kinase inhibitor (AG 1478) downregulated Bcl-x(L) expression in normal human keratinocytes but had no effect on expression of the pro-apoptotic Bcl-2 homologs Bad, Bak, and Bax. Bovine pituitary extract and insulin partially alleviated both, downregulation of Bcl-x(L) expression and cell death upon epidermal growth factor receptor inhibition. Forced expression of Bcl-x(L) attenuated cell death of immortalized keratinocytes (HaCaT) induced by either forced suspension (anoikis) or by epidermal growth factor receptor blockade. These results demonstrate that epidermal growth factor receptor-dependent signaling pathways control the balance of pro-apoptotic and anti-apoptotic Bcl-2 family members expressed in normal keratinocytes. Inappropriate survival supported by aberrant signaling through the epidermal growth factor receptor may contribute to the pathogenesis of psoriasis and of squamous cell carcinomas.
Subject(s)
ErbB Receptors/physiology , Keratinocytes/physiology , Proto-Oncogene Proteins c-bcl-2/physiology , Apoptosis , Cell Cycle , Cell Survival , Cells, Cultured , Humans , Transforming Growth Factor beta/pharmacology , bcl-X ProteinABSTRACT
The epidermis is a self-renewing tissue that must maintain a basal proliferative rate as well as respond to various perturbing stimuli. Regulation of keratinocyte proliferation involves diverse molecules, including growth factors, ions, and hormones. We recently proposed that a proteinase, urokinase-type plasminogen activator (uPA) may be added to this list, based on correlative evidence linking expression of uPA and murine epidermal hyperproliferation. Here we report that, during the first 3 d of life, the epidermis from mice that bear a targeted deletion of the uPA gene has a significantly lower proliferative rate than the epidermis from wild-type mice. In contrast, proliferation in the matrix keratinocytes of the hair follicles is not decreased in neonatal uPA-/- mice. Vertical migration of keratinocytes during terminal differentiation was not affected. We therefore conclude that lack of uPA is associated with a decrease in epidermal proliferation.
Subject(s)
Keratinocytes/cytology , Urokinase-Type Plasminogen Activator/pharmacology , Animals , Animals, Newborn , Bromodeoxyuridine , Cell Division/drug effects , Cell Movement , Hair Follicle/cytology , Mice , Mice, Inbred C57BL , Plasminogen Activators/pharmacology , Skin/enzymologyABSTRACT
In stratified squamous epithelia a critical balance among cell proliferation, differentiation, and death must be maintained in order for these tissues to fulfill their barrier function. Previous studies have demonstrated that plasminogen activator inhibitor 2 (PAI-2) is a product of differentiating epidermal keratinocytes, suggesting a role for this inhibitor during squamous differentiation. Furthermore, in certain tumor cell lines, overexpression of PAI-2 confers resistance to the induction of programmed cell death, suggesting cytoprotective function(s). In the present study we demonstrate that PAI-2 mRNA and protein are constitutively and uniquely expressed in differentiating cells of murine stratified squamous epithelia, including epidermis, esophagus, vagina, oral mucosa, and tongue. PAI-2 immunohistochemical localization patterns suggest a predominantly cytosolic distribution, consistent with biochemical identification of the major PAI-2 species as a 43-kDa, presumably non-glycosylated protein. Functional analysis shows that the majority of epithelial PAI-2 is active. In contrast to the high levels of PAI-2 expression in stratified squamous epithelia, little or no PAI-2 is detectable in simple epithelia. These findings suggest that epithelial PAI-2 may mediate inhibition of intracellular proteinases associated with events during terminal differentiation and death that are unique to stratified squamous epithelia.
Subject(s)
Epithelial Cells/metabolism , Plasminogen Activator Inhibitor 2/metabolism , Serine Proteinase Inhibitors/metabolism , Animals , Animals, Newborn , Cell Differentiation , Epidermis/metabolism , Esophagus/metabolism , Female , Immunoenzyme Techniques , Mice , Mice, Inbred C57BL , Mice, Inbred SENCAR , Mouth Mucosa/metabolism , Plasminogen Activator Inhibitor 2/genetics , RNA, Messenger/biosynthesis , Serine Proteinase Inhibitors/genetics , Tongue/metabolism , Vagina/metabolismABSTRACT
Plasminogen activator inhibitor type 2 (PAI-2) is an unusual member of the serine proteinase inhibitor (serpin) family which has been implicated in the protection of cells from programmed cell death. Human epidermal keratinocytes synthesize large amounts of PAI-2 in two active forms: glycosylated and non-glycosylated. Calcium (Ca2+), a well-known inducer of numerous aspects of keratinocyte terminal differentiation, increases the steady-state levels of PAI-2 mRNA and protein. As the cultures become more differentiated due to longer incubation with Ca2+, the glycosylated form is preferentially elevated. Surprisingly, glycosylated as well as non-glycosylated PAI-2 remains predominantly cell-associated, in a trypsin-inaccessible form and thus most likely inside the cell. Tumor necrosis factor-alpha (TNF-alpha), an inflammatory mediator that induces some markers of keratinocyte differentiation, also increases PAI-2 mRNA and protein levels. Experiments using cultures in which protein kinase C has been downregulated suggest that Ca2+, but not TNF-alpha, acts at least partially through one or more isozymes of this kinase for induction of PAI-2. This is consistent with the finding that the effect of simultaneous addition of Ca2+ plus TNF-alpha is at least additive, compared with addition of either stimulant alone. These data demonstrate that the keratinocyte maintains multiple regulatory pathways for control of PAI-2 expression, at least one of which is related to terminal differentiation.
Subject(s)
Calcium/pharmacology , Keratinocytes/drug effects , Plasminogen Activator Inhibitor 2/metabolism , Protein Kinase C/metabolism , Biomarkers , Cell Differentiation/drug effects , Cells, Cultured , Glycosylation , Humans , Keratinocytes/cytology , Tumor Necrosis Factor-alpha/pharmacologyABSTRACT
Protease activated receptors (PARs) compose a family of G protein signal transduction receptors activated by proteolysis. In this study, the susceptibility of PARs expressed on human keratinocytes and dermal fibroblasts to the human mast cell proteases tryptase and chymase was evaluated. PAR activation was measured by monitoring cytosolic [Ca2+] in cells loaded with the fluorescent Ca2+ probe Fura-2. Tryptase produced transient cytosolic Ca2+ mobilization in keratinocytes, but not in fibroblasts. Ca2+ mobilization in keratinocytes required enzymatically active tryptase, demonstrated desensitization, and was blocked by pretreatment of cells with the PAR-2 peptide agonist SLIGKV, trypsin, or the phospholipase inhibitor U73122. Heparin, a GAG that binds to tryptase, stabilizing its functional form, also inhibited tryptase-induced Ca2+ mobilization. The maximal response elicited by tryptase was smaller than that observed upon treatment of keratinocytes with trypsin, a known activator of PAR-2, and keratinocytes made refractory to tryptase by pretreatment with the protease remained responsive to trypsin. Pretreatment of keratinocytes with thrombin, an activator of PAR-1 and -3 (thrombin receptors), had no detectable effect on the tryptase or trypsin responses. These data suggest that in keratinocytes tryptase may be activating a subpopulation of PAR-2 receptors. Treatment of keratinocytes or fibroblasts with human chymase did not produce Ca2+ mobilization, nor did it affect Ca2+ mobilization produced by trypsin. However, chymase pretreatment of fibroblasts rapidly inhibited the ability of these cells to respond to thrombin. Inhibition was dependent on chymase enzymatic activity and was not significantly affected by the presence of heparin. This finding is consistent with studies indicating that PAR-1 may be susceptible to proteases with chymotrypsin-like specificity. These results suggest that the proteases tryptase and chymase secreted from mast cells in skin may affect the behavior of surrounding cells by the hydrolysis of PARs expressed by these cells.
Subject(s)
Mast Cells/enzymology , Mitogens/metabolism , Receptors, Thrombin/metabolism , Serine Endopeptidases/metabolism , Anticoagulants/pharmacology , Calcium/metabolism , Chymases , Cytosol/metabolism , Dose-Response Relationship, Drug , Fibroblasts/chemistry , Fibroblasts/cytology , Fibroblasts/enzymology , Fluorescent Dyes , Fura-2 , Hemostatics/pharmacology , Heparin/pharmacology , Humans , Keratinocytes/chemistry , Keratinocytes/cytology , Keratinocytes/enzymology , Receptor, PAR-1 , Receptor, PAR-2 , Skin/chemistry , Skin/cytology , Thrombin/pharmacology , TryptasesABSTRACT
Plasminogen activator inhibitor type 2 (PAI-2) is an unusual serine proteinase inhibitor in that it is largely retained within the cell and is found in high concentrations in the upper viable layers of human epidermis. Studies using transfected cell lines that express high levels of PAI-2 have suggested that this inhibitor may confer protection against programmed cell death. To test the hypothesis that PAI-2 may protect epithelial cells in vivo from premature programmed cell death, we determined expression patterns of PAI-2 in murine hair and nail. These epidermal derivatives are comprised of numerous epithelial cell types with distinct differentiation pathways. Furthermore, the cyclic nature of the follicular epithelium makes it ideal for studying sequential stages of cell differentiation and death. PAI-2 mRNA and protein were detected in the differentiating cells of the outer root sheath and medulla of the follicle during the anagen phase of the hair growth cycle. PAI-2 was also detected in the permanent portion of the catagen follicle. In the telogen phase of the hair growth cycle, PAI-2 was limited to the postmitotic cells of the outer root sheath directly abutting the club hair. In the nail, PAI-2 was detected in the differentiating cells of the matrix and nail bed. This consistent, selective distribution of PAI-2 in the postmitotic, maturing cells prior to terminal keratinization and death suggests that (i) PAI-2 may be considered as a differentiation marker for many epithelial cell types, and (ii) PAI-2 is appropriately positioned to protect epithelial cells from premature demise.